LeChat in oral pathology: Assessment of its immunohistochemical marker selection accuracy in salivary gland tumors

Artificial intelligence (AI) is increasingly integrated into pathology, but its accuracy in immunohistochemical (IHC) marker selection remains underexplored. This study evaluated LeChat’s ability to recommend IHC markers for benign and malignant salivary gland tumors, focusing on accuracy, completeness, relevance, consistency, and marker-level errors across tumor types and subtypes. A total of 21 tumor types were selected and classified by behavior (benign vs. malignant) and histologic subtype. Expert-derived reference panels served as the gold standard. For each tumor, LeChat was queried three times using standardized prompts. Recommendations were scored across three domains: accuracy (inclusion of essential markers), completeness (inclusion of secondary markers), and relevance (absence of irrelevant markers). Composite scores (range: 3–9) and intra-tumor variability were calculated. Mann–Whitney U and Kruskal–Wallis tests assessed differences by tumor category and subtype. Marker-level analysis evaluated over- and under-recommendations. Across 63 total prompts, LeChat achieved a mean accuracy of 1.56, completeness of 1.59, and relevance of 2.35. Only 3.2% of prompts included all essential markers, and 17.5% achieved composite scores ≥7. No responses included both primary and secondary markers. Performance did not differ significantly between benign and malignant tumors (p = 0.405), nor across histologic subtypes (p = 0.988). Tumor-level variability was highest for basaloid squamous cell carcinoma and lowest for pleomorphic adenoma. Marker-level analysis identified 14 false positives (e.g., CD20, IgG4) and 9 false negatives (e.g., SOX10, β-catenin). A moderate correlation was observed between marker frequency and accuracy (r = 0.48, p < 0.01). LeChat’s IHC recommendations were generally relevant but frequently incomplete and inconsistent, particularly for malignant and histologically complex tumors. Despite its potential for assisting in straightforward cases, current performance remains inferior to expert standards. These findings highlight the limitations of general-purpose LLMs in pathology workflows and emphasize the need for domain-specific refinement before clinical integration. • LeChat’s accuracy in IHC marker selection for salivary gland tumors was evaluated. • An expert consensus panel served as the gold standard for performance comparison. • LeChat showed moderate accuracy but low completeness in marker recommendations. • AI performance was most consistent in benign and myoepithelial salivary tumors. • Findings highlight AI’s potential and current limits in diagnostic histopathology.

Authors

Institutions

Publication Details

Journal
Oral Oncology Reports
Published
2026-01-03
DOI
https://doi.org/10.1016/j.oor.2025.100781
Primary Topic
Salivary Gland Tumors Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

LeChat in oral pathology: Assessment of its immunohistochemical marker selection accuracy in salivary gland tumors

Luca Fiorillo, Daniele Portelli, Javier Flores-Fraile, Wilmer Rodrigo Díaz-Castañeda et al.
Oral Oncology Reports
Salivary Gland Tumors Diagnosis and Treatment
article

LeChat in oral pathology: Assessment of its immunohistochemical marker selection accuracy in salivary gland tumors

Luca Fiorillo, Daniele Portelli, Javier Flores-Fraile, Wilmer Rodrigo Díaz-Castañeda, Vini Mehta, Cosimo Galletti, Maria-Teresa Fernández-Figueras, Maria Cuevas-Nunez, Shokoufeh Shahrabi Farahani
article en

Abstract

Artificial intelligence (AI) is increasingly integrated into pathology, but its accuracy in immunohistochemical (IHC) marker selection remains underexplored. This study evaluated LeChat’s ability to recommend IHC markers for benign and malignant salivary gland tumors, focusing on accuracy, completeness, relevance, consistency, and marker-level errors across tumor types and subtypes. A total of 21 tumor types were selected and classified by behavior (benign vs. malignant) and histologic subtype. Expert-derived reference panels served as the gold standard. For each tumor, LeChat was queried three times using standardized prompts. Recommendations were scored across three domains: accuracy (inclusion of essential markers), completeness (inclusion of secondary markers), and relevance (absence of irrelevant markers). Composite scores (range: 3–9) and intra-tumor variability were calculated. Mann–Whitney U and Kruskal–Wallis tests assessed differences by tumor category and subtype. Marker-level analysis evaluated over- and under-recommendations. Across 63 total prompts, LeChat achieved a mean accuracy of 1.56, completeness of 1.59, and relevance of 2.35. Only 3.2% of prompts included all essential markers, and 17.5% achieved composite scores ≥7. No responses included both primary and secondary markers. Performance did not differ significantly between benign and malignant tumors (p = 0.405), nor across histologic subtypes (p = 0.988). Tumor-level variability was highest for basaloid squamous cell carcinoma and lowest for pleomorphic adenoma. Marker-level analysis identified 14 false positives (e.g., CD20, IgG4) and 9 false negatives (e.g., SOX10, β-catenin). A moderate correlation was observed between marker frequency and accuracy (r = 0.48, p < 0.01). LeChat’s IHC recommendations were generally relevant but frequently incomplete and inconsistent, particularly for malignant and histologically complex tumors. Despite its potential for assisting in straightforward cases, current performance remains inferior to expert standards. These findings highlight the limitations of general-purpose LLMs in pathology workflows and emphasize the need for domain-specific refinement before clinical integration. • LeChat’s accuracy in IHC marker selection for salivary gland tumors was evaluated. • An expert consensus panel served as the gold standard for performance comparison. • LeChat showed moderate accuracy but low completeness in marker recommendations. • AI performance was most consistent in benign and myoepithelial salivary tumors. • Findings highlight AI’s potential and current limits in diagnostic histopathology.

Oral Oncology ReportsVol. 17
University of Messina (IT), University of Tennessee Health Science Center (US), Universidad de Salamanca (ES), Università degli Studi di Enna Kore (IT), Universitat Internacional de Catalunya (ES), Dr. D.Y. Patil Vidyapeeth, Pune (IN), Hospital General de Catalunya (ES), Dr D Y Patil Dental College & Hospital (IN)
Openalex Percentile: Top 98%
Salivary Gland Tumors Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.